|
PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING
|
Ongoing
|
emicizumab
|
4
|
MO401001
|
King Abdulaziz Medical City NG (Jeddah)
|
|
A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia
|
Ongoing
|
iGlarLixi
|
4
|
OBS17984
|
King Fahad Medical City (Riyadh)
|
|
REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line.
|
Ongoing
|
ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib,
|
4
|
22453
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study
|
Rejected
|
BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine
|
2
|
RJ19/119/J
|
King Abdulaziz Medical City NG (Jeddah)
|
|
A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1
|
Ongoing
|
Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™)
|
3
|
CTD-TCNPC-301
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism
|
Ongoing
|
RZ358
|
3
|
RZ358-301
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial
|
Ongoing
|
Bismuth Subcitrate Potassium , Tetracycline , Metronidazol
|
2
|
2231295
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
|
Ongoing
|
Giredestrant , Phesgo
|
3
|
WO43571
|
King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh)
|
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension
|
Ongoing
|
Baxdrostat
|
3
|
D6970C00009
|
King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
The effect of novel D3 use as a mouthwash in COVID-19 patients
|
Ongoing
|
Cholecalciferol (vitamin D)
|
3
|
2022-32
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
